Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27824110 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1MAPTRAB9ACA1 | |
| SCHEMBL13256587 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1MAPTRAB9ACA1 | |
| SCHEMBL29189867 | 0.88 | TDP1 (0.61) | SMN1; SMN2NPC1MAPTRAB9ALMNA | |
| SCHEMBL516998 | 0.86 | LMNA (0.72) | SMN1; SMN2NPC1MAPTRAB9ACA1 | |
| SCHEMBL11985689 | 0.86 | MAPT (0.73) | SMN1; SMN2NPC1MAPTRAB9ACA1 | |
| SCHEMBL20073174 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1MAPTRAB9ACA1 | |
| SCHEMBL12532606 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1MAPTRAB9ACA1 | |
| SCHEMBL22660277 | 0.83 | ESR1 (0.46) | SMN1; SMN2ESR1CYP2D6KMT2ACYP3A4 | |
| SCHEMBL1987834 | 0.83 | TSHR (0.68) | SMN1; SMN2NPC1MAPTRAB9ALMNA | |
| SCHEMBL18668887 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1MAPTRAB9ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190861-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-1751087-B1 | LEVODOPA DERIVATIVES, AND COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8163958-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110201817-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7956212-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342131-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1751087-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005121069-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | WILSHIRE PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201817-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | SMN1; SMN2 229/4885NPC1 3417/4885MAPT 1341/4885 |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | SMN1; SMN2 229/4885NPC1 3417/4885MAPT 1341/4885 |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | SMN1; SMN2 229/4885NPC1 3417/4885MAPT 1341/4885 |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | SMN1; SMN2 229/4885NPC1 3417/4885MAPT 1341/4885 |
| US-20120190861-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, DDT, DDC | SMN1; SMN2 229/4885NPC1 3417/4885MAPT 1341/4885 |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | SMN1; SMN2 229/4885NPC1 3417/4885MAPT 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.